Updates from the 2014 Annual Meeting of the American Society Hematology

Another hectic ASH has concluded. My pre-ASH expectations were largely confirmed with the full oral and poster presentations. But some important changes in philosophy and strategies for myeloma management emerged.

The IMF Goes to ASH: Trends, Topics, Progress and Education in Myeloma

To prepare for the upcoming 56th annual meeting of the American Society of Hematology (ASH), which will be held in San Francisco Dec.

Transplant at Relapse: Is It Valuable?

More than two dozen experts from around the world gathered in Minneapolis, Minn. Oct. 27, 2014 to assess the current landscape for autologousstem cell transplant (ASCT) as an option for myeloma patients who have relapsed. “Salvage” transplant—despite its rather gruesome-sounding name—offers an effective treatment choice for patients who have had a positive prior response to transplant.

Surprise rejection of panobinostat for approval by 5-2 margin at ODAC Hearing

Today's Oncologic Drugs Advisory Committee (ODAC) hearing convened in an optimistic fashion with many in the myeloma community expecting there would be a recommendation for approval of panobinostat, an HDAC inhibitor used in combination with Velcade and dexamethasone. Publicly available data indicated a 3.9 months progression-free survival (PFS) or remission duration benefit with the three-drug panobinostat combination in patients who had been treated with 1-3 prior therapies.

Diagnosing Myeloma Early: New IMWG Guidelines

For some time, members of theInternational Myeloma Working Group (IMWG), the IMF's research division, have been trying to identify and describe a group of patients without